Structural determinants of Smad function in TGF-β signaling

Trends in Biochemical Sciences

Volumn 40, Issue 6, 2015, Pages 296-308

  Macias, Maria J ^a,b   Martin Malpartida, Pau ^a   Massagué, Joan ^c  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer mutations; Smad conservation variation; Smad DNA binding; Smad proteins; Smad structure; Smad binding proteins; TGF signaling

Indexed keywords

SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; DNA BINDING PROTEIN;

CANCER CELL; CANCER INHIBITION; GENETIC VARIABILITY; HUMAN; METASTASIS; METASTATIC MELANOMA; NEGATIVE FEEDBACK; NONHUMAN; NONSENSE MUTATION; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SOMATIC MUTATION; CHEMISTRY; EMBRYO DEVELOPMENT; GENETIC TRANSCRIPTION; GENETICS; MUTATION; REGENERATION; STRUCTURE ACTIVITY RELATION;

METAZOA;

DNA-BINDING PROTEINS; EMBRYONIC DEVELOPMENT; HUMANS; MUTATION; REGENERATION; SIGNAL TRANSDUCTION; SMAD PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84929512126     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2015.03.012     Document Type: Review

References (72)

1. Massagué J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 6:753-791.
2. Massagué J. TGF-beta signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13:616-630.
3. Heldin C.H., et al. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 2009, 21:166-176.
4. Massagué J., et al. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.
5. Shi Y., Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
6. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
7. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J. Cell Sci. 2005, 118:3573-3584.
8. Beyer T.A., et al. Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 2013, 5:1611-1624.
9. Oshimori N., Fuchs E. The harmonies played by TGF-beta in stem cell biology. Cell Stem Cell 2012, 11:751-764.
10. Wu M.Y., Hill C.S. TGF-beta superfamily signaling in embryonic development and homeostasis. Dev. Cell 2009, 16:329-343.
11. Flavell R.A., et al. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10:554-567.
12. Ikushima H., Miyazono K. TGF-beta signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10:415-424.
13. Massagué J. TGF-beta in cancer. Cell 2008, 134:215-230.
14. Wrana J.L., et al. Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341-347.
15. Qin B.Y., et al. Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control. Genes Dev. 2002, 16:1950-1963.
16. Massagué J. TGF-beta signaling in development and disease. FEBS Lett. 2012, 586:1833.
17. Pardali E., et al. Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 2010, 20:556-567.
18. Alarcón C., et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009, 139:757-769.
19. Fuentealba L.C., et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 2007, 131:980-993.
20. Aragón E., et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev. 2011, 25:1275-1288.
21. Gao S., et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol. Cell 2009, 36:457-468.
22. Liu T., Feng X.H. Regulation of TGF-beta signalling by protein phosphatases. Biochem. J. 2010, 430:191-198.
23. Sapkota G., et al. Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J. Biol. Chem. 2006, 281:40412-40419.
24. Wrighton K.H., et al. Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling. J. Biol. Chem. 2006, 281:38365-38375.
25. Demagny H., et al. The tumor suppressor Smad4/DPC4 is regulated by phosphorylations that integrate FGF, Wnt, and TGF-beta signaling. Cell Rep. 2014, 9:688-700.
26. Kretzschmar M., et al. A mechanism of repression of TGF-beta/Smad signaling by oncogenic Ras. Genes Dev. 1999, 13:804-816.
27. Huminiecki L., et al. Emergence, development and diversification of the TGF-beta signalling pathway within the animal kingdom. BMC Evol. Biol. 2009, 9:28.
28. Richards G.S., Degnan B.M. The dawn of developmental signaling in the metazoa. Cold Spring Harb. Symp. Quant. Biol. 2009, 74:81-90.
29. Riesgo A., et al. The analysis of eight transcriptomes from all poriferan classes reveals surprising genetic complexity in sponges. Mol. Biol. Evol. 2014, 31:1102-1120.
30. Pang K., et al. Evolution of the TGF-beta signaling pathway and its potential role in the ctenophore, Mnemiopsis leidyi. PLoS ONE 2011, 6:e24152.
31. Srivastava M., et al. The Trichoplax genome and the nature of placozoans. Nature 2008, 454:955-960.
32. Srivastava M., et al. The Amphimedon queenslandica genome and the evolution of animal complexity. Nature 2010, 466:720-726.
33. Paabo S. The human condition - a molecular approach. Cell 2014, 157:216-226.
34. Hahn S.A., et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996, 56:490-494.
35. Eppert K., et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996, 86:543-552.
36. Hata A., et al. TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Mol. Med. Today 1998, 4:257-262.
37. Forbes S.A., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015, 43:D805-D811.
38. Skipper M. Cancer genomics: a panoramic view of cancer. Nat. Rev. Genet. 2013, 14:750.
39. Watson I.R., et al. Emerging patterns of somatic mutations in cancer. Nat. Rev. Genet. 2013, 14:703-718.
40. Baburajendran N., et al. Structural basis for the cooperative DNA recognition by Smad4 MH1 dimers. Nucleic Acids Res. 2011, 39:8213-8222.
41. Baburajendran N., et al. Structure of Smad1 MH1/DNA complex reveals distinctive rearrangements of BMP and TGF-beta effectors. Nucleic Acids Res. 2010, 38:3477-3488.
42. Chai J., et al. Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA binding. J. Biol. Chem. 2003, 278:20327-20331.
43. Shi Y., et al. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 1998, 94:585-594.
44. Chacko B.M., et al. Structural basis of heteromeric smad protein assembly in TGF-beta signaling. Mol. Cell 2004, 15:813-823.
45. Qin B.Y., et al. Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat. Struct. Biol. 2003, 10:913-921.
46. Shi Y., et al. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997, 388:87-93.
47. Wu G., et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 2000, 287:92-97.
48. Wu J.W., et al. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol. Cell 2001, 8:1277-1289.
49. Krivov G.G., et al. Improved prediction of protein side-chain conformations with SCWRL4. Proteins 2009, 77:778-795.
50. Brown S., et al. Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors. Stem Cells 2011, 29:1176-1185.
51. Grishin N.V., et al. MH1 domain of Smad is a degraded homing endonuclease. J. Mol. Biol. 2001, 307:31-37.
52. Jones J.B., Kern S.E. Functional mapping of the MH1 DNA-binding domain of DPC4/SMAD4. Nucleic Acids Res. 2000, 28:2363-2368.
53. Xu J., Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:4820-4825.
54. Hata A., et al. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 1997, 388:82-87.
55. Zawel L., et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1998, 1:611-617.
56. Dunn N.R., et al. Combinatorial activities of Smad2 and Smad3 regulate mesoderm formation and patterning in the mouse embryo. Development 2004, 131:1717-1728.
57. Iordanou E., et al. The novel Smad protein Expansion regulates the receptor tyrosine kinase pathway to control Drosophila tracheal tube size. Dev. Biol. 2014, 393:93-108.
58. Moussian B., et al. Deciphering the genetic programme triggering timely and spatially-regulated chitin deposition. PLoS Genet. 2015, 11:e1004939.
59. Beich-Frandsen M., et al. Structure of the N-terminal domain of the protein Expansion: an 'Expansion' to the Smad MH2 fold. Acta Crystallogr. 2015, D71:844-853.
60. Takahasi K., et al. X-ray crystal structure of IRF-3 and its functional implications. Nat. Struct. Biol. 2003, 10:922-927.
61. Lo R.S., et al. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. EMBO J. 1998, 17:996-1005.
62. Tsukazaki T., et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998, 95:779-791.
63. Shi W., et al. Endofin acts as a Smad anchor for receptor activation in BMP signaling. J. Cell Sci. 2007, 120:1216-1224.
64. Macias M.J., et al. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands. FEBS Lett. 2002, 513:30-37.
65. Gaspar P., Tapon N. Sensing the local environment: actin architecture and Hippo signalling. Curr. Opin. Cell Biol. 2014, 31:74-83.
66. Pan D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19:491-505.
67. Piccolo S., et al. The biology of YAP/TAZ: hippo signaling and beyond. Physiol. Rev. 2014, 94:1287-1312.
68. Cheng P.L., et al. Phosphorylation of E3 ligase Smurf1 switches its substrate preference in support of axon development. Neuron 2011, 69:231-243.
69. Nakao A., et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997, 389:631-635.
70. Inoue Y., Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci. 2008, 99:2107-2112.
71. Aragón E., et al. Structural basis for the versatile interactions of Smad7 with regulator WW domains in TGF-beta pathways. Structure 2012, 20:1726-1736.
72. Chong P.A., et al. An expanded WW domain recognition motif revealed by the interaction between Smad7 and the E3 ubiquitin ligase Smurf2. J. Biol. Chem. 2006, 281:17069-17075.